Landos Biopharma, Inc. (LABP)

Market Cap	10.67M
Revenue (ttm)	n/a
Net Income (ttm)	-39.28M
Shares Out	40.25M
EPS (ttm)	-0.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,554
Open	0.243
Previous Close	0.260
Day's Range	0.243 - 0.277
52-Week Range	0.211 - 1.920
Beta	-1.13
Analysts	Sell
Price Target	2.75 (+937.74%)
Earnings Date	May 10, 2023

About LABP

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor assoc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2021
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: LABP

Analyst Forecast

According to 9 analysts, the average rating for LABP stock is "Sell." The 12-month stock price forecast is $2.75, which is an increase of 937.74% from the latest price.

Price Target

$2.75

(937.74% upside)

Analyst Consensus: Sell